1. A review of FLT3 inhibitors in acute myeloid leukemia;Zhao J. C.;Blood Rev.,2022
2. Midostaurin: First global approval;Kim K. S.;Drugs.,2017
3. Blueprint's Ayvakit expected to take Novartis’ Rydapt crown in advanced systemic mastocytosis but off‐label use in indolent unlikely;Rai‐Roche Sean;Clinical Trials Arena.,2021
4. Boulevard of broken dreams: Drug approval for older adults with acute myeloid leukemia;Sekeres M. A.;J Clin. Oncol.,2012
5. Midostaurin, enasidenib, CPX‐351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML;Wei A. H.;Blood,2017